These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21161752)

  • 21. The GABA-B positive modulator GS39783 decreases psychostimulant conditioned-reinforcement and conditioned-reward.
    Halbout B; Quarta D; Valerio E; Heidbreder CA; Hutcheson DM
    Addict Biol; 2011 Jul; 16(3):416-27. PubMed ID: 21309927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The principles of agonist pharmacotherapy for psychostimulant dependence.
    Shearer J
    Drug Alcohol Rev; 2008 May; 27(3):301-8. PubMed ID: 18368612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests.
    Zernig G; Ahmed SH; Cardinal RN; Morgan D; Acquas E; Foltin RW; Vezina P; Negus SS; Crespo JA; Stöckl P; Grubinger P; Madlung E; Haring C; Kurz M; Saria A
    Pharmacology; 2007; 80(2-3):65-119. PubMed ID: 17570954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychostimulants: Basic and Clinical Pharmacology.
    McCreary AC; Müller CP; Filip M
    Int Rev Neurobiol; 2015; 120():41-83. PubMed ID: 26070753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breaking the loop: oxytocin as a potential treatment for drug addiction.
    McGregor IS; Bowen MT
    Horm Behav; 2012 Mar; 61(3):331-9. PubMed ID: 22198308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of CART in the reward/reinforcing properties of psychostimulants.
    Jaworski JN; Jones DC
    Peptides; 2006 Aug; 27(8):1993-2004. PubMed ID: 16766084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the relationship between anxiety during withdrawal and stress-induced reinstatement of cocaine seeking.
    Erb S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Jun; 34(5):798-807. PubMed ID: 19969038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?
    Pierce RC; Kumaresan V
    Neurosci Biobehav Rev; 2006; 30(2):215-38. PubMed ID: 16099045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anhedonia and substance dependence: clinical correlates and treatment options.
    Hatzigiakoumis DS; Martinotti G; Giannantonio MD; Janiri L
    Front Psychiatry; 2011; 2():10. PubMed ID: 21556280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine receptor agonists, partial agonists and psychostimulant addiction.
    Pulvirenti L; Koob GF
    Trends Pharmacol Sci; 1994 Oct; 15(10):374-9. PubMed ID: 7809953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anhedonia, Hyperkatifeia, and Negative Reinforcement in Substance Use Disorders.
    Koob GF
    Curr Top Behav Neurosci; 2022; 58():147-165. PubMed ID: 35112332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the brain reward system in depression.
    Naranjo CA; Tremblay LK; Busto UE
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 May; 25(4):781-823. PubMed ID: 11383978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The neurobiology of anhedonia. The pathophysiology of an important symptom in depressive disorders].
    Kuhlmann SR; Walter H; Schläpfer TE
    Nervenarzt; 2013 May; 84(5):590-5. PubMed ID: 23086440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on neuroscience and behavior.
    Neuroscientist; 2012 Aug; 18(4):310-1. PubMed ID: 23019662
    [No Abstract]   [Full Text] [Related]  

  • 35. Preclinical studies on comorbidity between depression and psychostimulant addiction.
    Filip M; Frankowska M; Jastrzębska J; Wydra K; Przegaliński E
    Pharmacol Rep; 2013; 65(6):1529-34. PubMed ID: 24553001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychostimulant addiction treatment.
    Phillips KA; Epstein DH; Preston KL
    Neuropharmacology; 2014 Dec; 87():150-60. PubMed ID: 24727297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysregulation of Acetylation Enzymes Inanimal Models of Psychostimulant use Disorders: Evolving Stories.
    Lud Cadet J
    Curr Neuropharmacol; 2016; 14(1):10-6. PubMed ID: 26813118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Provocative tests with psychostimulant drugs in schizophrenia.
    Lieberman JA; Kane JM; Alvir J
    Psychopharmacology (Berl); 1987; 91(4):415-33. PubMed ID: 2884687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Protective Effect of Social Reward on Opioid and Psychostimulant Reward and Relapse: Behavior, Pharmacology, and Brain Regions.
    Venniro M; Marino RAM; Chow JJ; Caprioli D; Epstein DH; Ramsey LA; Shaham Y
    J Neurosci; 2022 Dec; 42(50):9298-9314. PubMed ID: 36517252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anhedonia in substance use disorders: a systematic review of its nature, course and clinical correlates.
    Garfield JB; Lubman DI; Yücel M
    Aust N Z J Psychiatry; 2014 Jan; 48(1):36-51. PubMed ID: 24270310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.